Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck
Oral Oncology , 04/19/2012Perez CA et al.
Gefitinib has clinical activity as monotherapy in squamous cell carcinoma of the head and neck (SCCHN). Dose escalation of gefitinib is feasible and may increase skin toxicity, but the data do not support increased activity.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.